These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 25794045

  • 1. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, Knerer G.
    PLoS One; 2015; 10(3):e0120763. PubMed ID: 25794045
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X, Smare C, Kambili C, El Khoury AC, Wolfson LJ.
    BMC Health Serv Res; 2017 Jan 26; 17(1):87. PubMed ID: 28122562
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q, Ming WK, Yip WY, You JHS.
    Int J Infect Dis; 2019 Jan 26; 78():44-49. PubMed ID: 30342251
    [Abstract] [Full Text] [Related]

  • 7. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A, Williams A, Kambili C, Mattson G, Metz L.
    Expert Rev Anti Infect Ther; 2020 May 26; 18(5):475-483. PubMed ID: 32186925
    [Abstract] [Full Text] [Related]

  • 8. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E.
    Int J Tuberc Lung Dis; 2018 Aug 01; 22(8):918-925. PubMed ID: 29991402
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
    Park HY, Ku HM, Sohn HS, Seo HS, Yung Lee H, Hwa Lim K, Kwon JW.
    Clin Ther; 2016 Mar 01; 38(3):655-67.e1-2. PubMed ID: 26907504
    [Abstract] [Full Text] [Related]

  • 10. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP, Klaassen F, Sweeney S, Furin J, Franke MF, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies NA.
    PLoS Med; 2024 May 01; 21(5):e1004401. PubMed ID: 38701084
    [Abstract] [Full Text] [Related]

  • 11. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, Dakum P, Abimiku A.
    PLoS One; 2020 May 01; 15(12):e0241065. PubMed ID: 33259492
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ, Gibbert J, Wirth D, Diel R.
    Eur Respir J; 2015 Dec 01; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy.
    Codecasa LR, Toumi M, D'Ausilio A, Aiello A, Damele F, Termini R, Uglietti A, Hettle R, Graziano G, De Lorenzo S.
    J Mark Access Health Policy; 2017 Dec 01; 5(1):1283105. PubMed ID: 28265350
    [Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China.
    Xu CH, Qiu YP, He ZL, Hu DM, Yue X, Chen ZD, Xu YY, Zhao YL.
    Biomed Environ Sci; 2023 Jun 20; 36(6):501-509. PubMed ID: 37424243
    [Abstract] [Full Text] [Related]

  • 15. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM, Mpobela Agnarson A, Kambili C, Metz L, Kfoury J, Wang S, Williams A, Singh V, Thomas A.
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec 20; 18(6):677-689. PubMed ID: 30073886
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, Lomtadze N, Avaliani Z, Kiria N, Malhotra S, Cook-Scalise S, Juneja S, Everitt D, Spigelman M, Vassall A.
    BMJ Open; 2021 Dec 03; 11(12):e051521. PubMed ID: 34862287
    [Abstract] [Full Text] [Related]

  • 17. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A, Cobelens FG, Cohen T.
    PLoS Med; 2016 Oct 03; 13(10):e1002142. PubMed ID: 27727274
    [Abstract] [Full Text] [Related]

  • 18. A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.
    Manalan K, Green N, Arnold A, Cooke GS, Dedicoat M, Lipman M, Loyse A, Harrison TS, Kon OM.
    J Infect; 2020 Jan 03; 80(1):38-41. PubMed ID: 31550466
    [Abstract] [Full Text] [Related]

  • 19. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
    Alemayehu S, Yigezu A, Hailemariam D, Hailu A.
    PLoS One; 2020 Oct 25; 15(7):e0235820. PubMed ID: 32716915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.